JO3551B1 - تركيبة كبسولة مشتملة على المونتليوكاست و اللِّيفوسيتريزين - Google Patents

تركيبة كبسولة مشتملة على المونتليوكاست و اللِّيفوسيتريزين

Info

Publication number
JO3551B1
JO3551B1 JOP/2012/0182A JOP20120182A JO3551B1 JO 3551 B1 JO3551 B1 JO 3551B1 JO P20120182 A JOP20120182 A JO P20120182A JO 3551 B1 JO3551 B1 JO 3551B1
Authority
JO
Jordan
Prior art keywords
levocetirizine
montelukast
pharmaceutically acceptable
acceptable salt
layer
Prior art date
Application number
JOP/2012/0182A
Other languages
English (en)
Inventor
Soo Woo Jong
Ho Kim Dong
Ii Kim Yong
Kwan Kwon Taek
Soo Kim Kyeong
Hyun Park Jae
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47839311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3551(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Application granted granted Critical
Publication of JO3551B1 publication Critical patent/JO3551B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتم الكشف عن تركيبة كبسولة لوقاية أو علاج التهاب الأنف الأرجي وداء الربو وتتألف التركيبة من طبقتين منفصلتين وهما: طبقة مونتيلوكاست التي تحتوي مونتيلوكاست أو ملحه المقبول صيدلانيا؛ و (2) طبقة ليفوسيتريزين تحتوي على ليفوسيتريزين أو ملحه المقبول صيدلانيا؛ وطريقة لإعدادهما. <br /> يمكن أن تفصل تركيبة الكبسولة حسب هذا الاختراع المكونين النشطين فصلا بالكامل مما يقلل من التفاعلية بينهما وتحسين من استقرار المنتج ضد آثار الشيخوخة، وبالتالي يحسن من الآثار العلاجية.
JOP/2012/0182A 2011-07-15 2012-07-08 تركيبة كبسولة مشتملة على المونتليوكاست و اللِّيفوسيتريزين JO3551B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110070680 2011-07-15
KR1020110111132A KR20130009553A (ko) 2011-07-15 2011-10-28 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제

Publications (1)

Publication Number Publication Date
JO3551B1 true JO3551B1 (ar) 2020-07-05

Family

ID=47839311

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0182A JO3551B1 (ar) 2011-07-15 2012-07-08 تركيبة كبسولة مشتملة على المونتليوكاست و اللِّيفوسيتريزين

Country Status (22)

Country Link
US (2) US20140170213A1 (ar)
EP (1) EP2731594B1 (ar)
JP (1) JP2014520842A (ar)
KR (2) KR20130009553A (ar)
CN (2) CN103687591A (ar)
AR (1) AR087177A1 (ar)
BR (1) BR112014000943A2 (ar)
CL (1) CL2014000054A1 (ar)
CO (1) CO6880062A2 (ar)
ES (1) ES2727861T3 (ar)
HK (1) HK1246199A1 (ar)
JO (1) JO3551B1 (ar)
MX (1) MX366509B (ar)
MY (1) MY178890A (ar)
PE (1) PE20141200A1 (ar)
PH (1) PH12014500066A1 (ar)
RU (1) RU2606857C2 (ar)
SA (1) SA112330689B1 (ar)
TW (1) TW201311241A (ar)
UA (1) UA112083C2 (ar)
WO (1) WO2013012199A1 (ar)
ZA (1) ZA201401143B (ar)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107308161A (zh) 2010-06-16 2017-11-03 炎症反应研究股份有限公司 左西替利嗪和孟鲁司特在治疗流感、普通感冒和炎症中的用途
KR101418404B1 (ko) * 2012-01-06 2014-07-10 한미약품 주식회사 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제
RU2677649C2 (ru) * 2013-02-21 2019-01-18 Глэнмарк Фармасьютикалс Лимитед Фармацевтические композиции монтелукаста и левоцетиризина
JP2016512262A (ja) 2013-03-13 2016-04-25 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 血管炎の処置におけるレボセチリジン及びモンテルカストの使用
EP2969001B1 (en) * 2013-03-13 2018-12-19 IRR, Inc. Use of levocetirizine and montelukast in the treatment of anaphylaxis
HK1222818A1 (zh) * 2013-03-13 2017-07-14 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗创伤性损伤中的用途
JP6441888B2 (ja) 2013-03-13 2018-12-19 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 自己免疫性障害の処置におけるレボセチリジン及びモンテルカストの使用
KR102226833B1 (ko) * 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
WO2015069203A1 (en) * 2013-11-06 2015-05-14 Santa Farma Ilaç Sanayi A.Ş. Capsule comprising rupatadine fumarate and montelukast sodium
KR101669556B1 (ko) * 2014-07-02 2016-10-28 한미약품 주식회사 몬테루카스트 또는 이의 약제학적으로 허용가능한 염의 경구투여용 액상제제
JP6575031B2 (ja) * 2014-07-28 2019-09-18 日本ケミファ株式会社 モンテルカストナトリウム製剤
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
PL3222279T3 (pl) 2016-03-21 2022-05-09 Invest Bielany Spółka Z Ograniczoną Odpowiedzialnością Doustny preparat farmaceutyczny montelukastu i lewocetyryzyny oraz sposób jego wytwarzania
AU2018253392B2 (en) 2017-04-14 2023-11-02 Capsugel Belgium Nv Process for making pullulan
ES3033915T3 (en) 2017-04-14 2025-08-11 Capsugel Belgium Nv Pullulan capsules
KR20210152280A (ko) 2020-06-08 2021-12-15 주식회사 경보제약 몬테루카스트와 레보세티리진을 포함하는 안정성이 향상된 단일 정제 및 이의 제조방법
KR102481517B1 (ko) 2021-08-30 2022-12-27 주식회사 클라시아 약제학적 제제
EP4321156A4 (en) 2021-10-21 2025-05-07 Han Wha Pharma Co., Ltd. FILM-COATED TABLET WITH IMPROVED STABILITY CONTAINING MONTELUKAST OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND LEVOCETIRIZINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT
KR20240045586A (ko) 2022-09-30 2024-04-08 주식회사 제뉴원사이언스 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 포함하는 안정성이 향상된 이층정 정제 및 그의 제조방법
KR20250005771A (ko) 2023-07-03 2025-01-10 경동제약 주식회사 레보세티리진 및 몬테루카스트를 포함하는 복합 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2588188B1 (fr) * 1985-10-04 1988-01-08 Delalande Sa Comprime de sel(s) hydrosoluble(s) de cinepazide a liberation programmee et son procede de preparation
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
JPH08501561A (ja) 1992-09-24 1996-02-20 セプラコア，インコーポレイテッド （−）セチリジンを用いたアレルギー疾患の治療のための組成物
RU2108787C1 (ru) * 1993-09-01 1998-04-20 Роммерс С.А.И.С.Ф. Фармацевтические мягкие капсулы, содержащие лизинхлониксинат, способ их получения
CN1283115A (zh) * 1997-12-23 2001-02-07 先灵公司 用于治疗呼吸道和皮肤病的含有至少一种白三烯拮抗剂和至少一种抗组胺药的组合物
IL159287A0 (en) * 2001-06-28 2004-06-01 Ucb Farchim Sa Tablet comprising cetirizine and pseudoephedrine
DK1404304T3 (da) 2001-06-28 2009-07-13 Ucb Farchim Sa Tablet omfattende cetirizin og pseudoephedrin
WO2005089171A2 (en) * 2004-03-11 2005-09-29 Mullally John P Protocol for improving vision
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
CN101073563B (zh) * 2007-02-07 2010-10-06 西安利君制药有限责任公司 一种含有右旋布洛芬和左旋西替利嗪的手性组合物及其缓速释双层片
US20120015032A1 (en) * 2007-08-13 2012-01-19 Hanall Pharmaceutical Company, Ltd. Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
RU2405542C2 (ru) * 2008-11-19 2010-12-10 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Мягкая экструзионная капсула, способ приготовления раствора для ее наполнения, способ получения капсул и способ увеличения плотности агаровой оболочки
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations

Also Published As

Publication number Publication date
RU2014105577A (ru) 2015-08-27
RU2606857C2 (ru) 2017-01-10
BR112014000943A2 (pt) 2017-02-14
WO2013012199A8 (en) 2014-02-06
EP2731594A4 (en) 2014-12-31
US20140170213A1 (en) 2014-06-19
US20160089339A1 (en) 2016-03-31
SA112330689B1 (ar) 2017-03-02
CL2014000054A1 (es) 2014-07-11
PH12014500066A1 (en) 2014-03-24
PE20141200A1 (es) 2014-09-29
CN107468667A (zh) 2017-12-15
AR087177A1 (es) 2014-02-26
MX366509B (es) 2019-07-11
HK1246199A1 (zh) 2018-09-07
UA112083C2 (uk) 2016-07-25
CN103687591A (zh) 2014-03-26
ZA201401143B (en) 2015-04-29
EP2731594B1 (en) 2019-04-24
TW201311241A (zh) 2013-03-16
EP2731594A1 (en) 2014-05-21
WO2013012199A1 (en) 2013-01-24
MX2014000312A (es) 2014-02-19
KR20180090966A (ko) 2018-08-14
KR20130009553A (ko) 2013-01-23
KR102006000B1 (ko) 2019-08-01
MY178890A (en) 2020-10-21
ES2727861T3 (es) 2019-10-21
CO6880062A2 (es) 2014-02-28
JP2014520842A (ja) 2014-08-25

Similar Documents

Publication Publication Date Title
JO3551B1 (ar) تركيبة كبسولة مشتملة على المونتليوكاست و اللِّيفوسيتريزين
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
CR20160327A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
EA201390049A1 (ru) Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
BR112014004435A2 (pt) inibidores de quinase rock
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
HK1247838A1 (zh) 骨质疏松症的治疗
WO2011086531A3 (en) New anti-malarial agents
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
WO2013147649A3 (ru) ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
EA201291306A1 (ru) Состав сухого порошка, содержащий антимускариновое средство
EA201691402A1 (ru) Фармацевтический препарат, содержащий соединение пиридиламиноуксусной кислоты
MX362485B (es) Nuevos inhibidores de rock.
AU2012277905A8 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
MD20130005A2 (ro) Compoziţie farmaceutică cu eliberare prelungită a trimetazidinei
PH12015501407A1 (en) Topical opthalmological pharmaceutical composition containing regorafenib
BR112014004737A2 (pt) composto de composição de cloridrato de ambroxol e método de preparação do composto
EA029678B9 (ru) Четвертичные соли пиперидиния
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
CY1122598T1 (el) Οφθαλμικη φαρμακευτικη συνθεση περιεχουσα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτης
PL3882244T3 (pl) ZWIĄZEK, JEGO FARMACEUTYCZNIE DOPUSZCZALNA SÓL LUB IZOMER OPTYCZNY, SPOSÓB ICH WYTWARZANIA i ZAWIERAJĄCA JE, JAKO SKŁADNIK AKTYWNY, KOMPOZYCJA FARMACEUTYCZNA DO PROFILAKTYKI LUB LECZENIA CHORÓB WIRUSOWYCH